Main distributor to Brazil and Latin America for analytical reference substances  |  Welcome! Olá! Hola! Español  |  +1.919.484.7555
You are here: Home /News

News

E. coli superbug strains can persist in healthy women’s guts — ScienceDaily

A recent study of over 1,000 healthy women with no symptoms of urinary tract infections showed nearly 9 percent carried multi-drug resistant Escherichia coli strains in their guts. This is of clinical concern because disease-causing E. coli bacteria can transfer from the digestive tract to the female urinary tract via the urethra, the urine duct, which is […]

Posted in Science | Comments Off on E. coli superbug strains can persist in healthy women’s guts — ScienceDaily

US senators introduce bipartisan bill to lower drug prices

US Senate Finance Committee chairman Chuck Grassley and ranking member Ron Wyden have introduced a bipartisan bill aimed at lowering drug prices in the country. The Prescription Drug Pricing Reduction Act (PDPRA) asks for penalisation of pharmaceutical companies that increase Medicare prices more than inflation. Drugmakers will require rebates to be paid equivalent to the […]

Posted in USA | Comments Off on US senators introduce bipartisan bill to lower drug prices

FDA approves nine generics of Pfizer’s Lyrica drug

SHARE Lyrica is a prescription medicine cleared by the FDA for the treatment of various pain indications. Credit: Vaccinationist. The US Food and Drug Administration (FDA) has approved nine generic versions of Pfizer’s nerve pain drug Lyrica (pregabalin), which are the first generics approved for the medication. Lyrica is a prescription medicine cleared by the […]

Posted in FDA | Comments Off on FDA approves nine generics of Pfizer’s Lyrica drug

Myovant reports uterine fibroid combination therapy results

UK healthcare company Myovant Sciences has announced positive results from LIBERTY 2, its second Phase III study of relugolix combination therapy. The trial met its primary efficacy endpoint with a 71.2% response rate, as well assix key secondary endpoints in women with uterine fibroids. The Phase III programme consisted of two duplicate, pivotal clinical studies […]

Posted in Research | Comments Off on Myovant reports uterine fibroid combination therapy results

BMS’ Opdivo fails to meet primary endpoint in NSCLC

Bristol-Myers Squibb (BMS) has announced that its immunotherapy Opvido (nivolumab) plus chemotherapy failed to meet its primary endpoint of overall survival (OS) in the Phase III CheckMate-227 trial of patients with first-line non-squamous non-small cell lung cancer (NSCLC). Opdivo is a PD-1 immune checkpoint inhibitor that harnesses the body’s immune system to fight cancer. It […]

Posted in Cancer | Comments Off on BMS’ Opdivo fails to meet primary endpoint in NSCLC

Operations in pharmaceutical industry: simplification and behaviour change

NSF International’s Pharmaceutical executive director Jim Morris’s webinar, Implementing a Simplification Strategy, describes several ways to increase the efficiency of a production plant by helping operators execute tasks with greater consistency and confidence, and less effort. A key principle is to ensure a reduction of cognitive load for personnel who work in the operational side of […]

Posted in Business | Comments Off on Operations in pharmaceutical industry: simplification and behaviour change

Novartis’ combination asthma drug meets endpoints in Phase II study

QMF149 combines a long-acting beta antagonist with an anti-inflammatory drug. Credit: FSP Vintage Collection. Swiss drug maker Novartis has announced its investigational, combination asthma drug QMF149 met both its primary and secondary endpoints in the Phase III QUARTZ trial. QMF149 is a once-daily, low dose combination treatment containing indacaterol acetate (ICD), a long-acting beta agonist, […]

Posted in Drug | Comments Off on Novartis’ combination asthma drug meets endpoints in Phase II study

Lynparza reduces PFS in germline BRCA-mutated pancreatic cancer

AstraZeneca and Merck have announced that Lynparza (olaparib) demonstrated significant improvement in progression-free survival (PFS), compared to placebo, in germline BRCA-mutated metastatic .adenocarcinoma of the pancreas. In the Phase III POLO trial, researches only studied patients whose disease had not progressed following platinum-based chemotherapy, which is the current the standard of care. Lynparza improved time […]

Posted in Cancer, Research | Comments Off on Lynparza reduces PFS in germline BRCA-mutated pancreatic cancer

Pembrolizumab trumps chemotherapy in recurrent head and neck cancer

Research has shown that immunotherapy pembrolizumab alone and in combination with chemotherapy is a more efficacious first line treatment for head and neck cancer that has returned than aggressive chemotherapy. The research was led by the Institute of Cancer Research (ICR), London and The Royal Marsden NHS Foundation Trust, but carried out across 206 sites […]

Posted in Cancer | Comments Off on Pembrolizumab trumps chemotherapy in recurrent head and neck cancer

Targeted therapy proves effective against aggressive rare blood cancer: Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease

A multi-institutional clinical trial has given good results for a targeted therapy to treat a rare, aggressive blood cancer known as blastic plasmacytoid dendritic-cell neoplasm (BPDCN). Details on the trial, which supported Food and Drug Administration approval of the tagraxofusp therapy in December 2018, have been published in the New England Journal of Medicine. Diagnosed in […]

Posted in FDA | Comments Off on Targeted therapy proves effective against aggressive rare blood cancer: Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease